Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Katowice – page 27

736 clinical trials in Katowice, Poland across 18 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Katowice at a glance
736
clinical trials
  • Research sites18
Type of trial
Recruitment status
Quick filters

736 trials in Katowice

Open in trial search

Major depression

Not yet recruiting

Long‑Term Safety, Tolerability and Efficacy of Azetukalner in Patients with Major Depressive Disorder

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Neuroendocrine tumour

Not yet recruiting

Evaluation of V-Cu64 versus V-Ga68 PET-CT imaging in adults with diagnosed or suspected neuroendocrine tumors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Edotreotide

Rheumatoid arthritis

Not yet recruiting

ELV001 for Active Rheumatoid Arthritis in Patients with Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ZAMPILIMAB
  • Sponsor:Chiesi Farmaceutici S.p.A.

Dermatitis atopic

Not yet recruiting

Phase 2b Randomized Double‑Blind Study of Oral PF‑08049820 in Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Sponsor:Pfizer Inc.

Parkinson's disease

Not yet recruiting

A study to optimize the delivery of AAV2-GDNF and gadoteridol into the brain for patients with Parkinson's disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Gadoteridol
  • Sponsor:Askbio Inc.

Bipolar I disorder

Not yet recruiting

A study to evaluate the effectiveness and safety of azetukalner in patients experiencing depressive episodes associated with bipolar disorder.

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Regeneron Pharmaceuticals Inc.

Endocrine ophthalmopathy

Not yet recruiting

A study testing teprotumumab compared to placebo in adult patients with moderate-to-severe active thyroid eye disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Multiple system atrophy+1

Not yet recruiting

Long-term safety and effectiveness follow-up study of AB-1005 gene therapy in patients with Parkinson's disease or multiple system atrophy

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carbidopa
  • Sponsor:Askbio Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Katowice

What the registry says about research in the country

01 Respiratory Conditions

Research focusing on respiratory health conditions, including studies on RSV infections in older adults and treatments for chronic obstructive pulmonary disease. Current trials are evaluating new vaccines and investigating innovative therapies for chronic rhinosinusitis.

  • RSV Vaccine Studies
  • COPD Treatment Evaluation
  • Chronic Rhinosinusitis Management
02 Neurological Disorders

Innovative research into neurodegenerative conditions, with a particular focus on Parkinson's disease treatments. Studies are examining new therapeutic approaches and investigating targeted treatments for early-stage Parkinson's.

  • Early Parkinson's Disease Interventions
  • LRRK2-Driven Parkinson's Research
  • Generalized Myasthenia Gravis Treatment
03 Dermatological Conditions

Comprehensive studies on inflammatory skin conditions, including trials for moderate to severe plaque psoriasis, genital psoriasis, and atopic dermatitis. Research focuses on evaluating new biological treatments and innovative therapies.

  • Plaque Psoriasis Treatments
  • Atopic Dermatitis Management
  • Novel Therapeutic Approaches
04 Oncology and Hematology

Advanced research in cancer treatment, particularly focusing on blood cancers and prostate cancer. Studies include innovative approaches for treating diffuse large B-cell lymphoma and acute myeloid leukemia.

  • Lymphoma Therapies
  • Leukemia Treatments
  • Prostate Cancer Management
05 Autoimmune Conditions

Research investigating treatments for various autoimmune disorders, including Sjögren's Syndrome and chronic inflammatory demyelinating polyneuropathy. Studies focus on evaluating new therapeutic agents and their long-term effectiveness.

  • Sjögren's Disease Therapies
  • CIDP Treatment Approaches
  • Inflammatory Disease Management
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.